贝前列素钠联合沙库巴曲缬沙坦钠片对原发性高血压合并早期肾功能不全的疗效及安全性分析  

The Efficacy and Safety Analysis of Beprost Sodium Combined with Sacubactril Valsartan Sodium Tablets in the Treatment of Essential Hypertension with Early Renal Insufficiency

作　　者：张娜[1] 刘海明[1] 陈曦[1] 侯宪庚 张俊仕[1] ZHANG Na;LIU Hai-ming;CHEN Xi;HOU Xian-geng;ZHANG Jun-shia(Department of Hypertension,The First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang,830000,China)

机构地区：[1]新疆医科大学第一附属医院高血压科,新疆乌鲁木齐830000

出　　处：《现代生物医学进展》2024年第20期3878-3880,共3页Progress in Modern Biomedicine

基　　金：新疆维吾尔自治区自然科学基金项目(2022D01C238)。

摘　　要：目的:探讨贝前列素钠联合沙库巴曲缬沙坦钠片的效果及安全性。方法:选择2022年6月至2023年12月来我院诊治的原发性高血压合并早期肾功能不全患者106例,分为对照组、观察组,每组取患者为53例。对照组:贝前列素钠,观察组:沙库巴曲缬沙坦钠片+贝前列素钠。对比两组相关指标。结果:与对照组相比,观察组疗效高(P<0.05)。治疗后,两组CCr,Cys C、β2-MG、MAU水平、eGFR、24 h舒张压/收缩压变异性、白昼舒张压/收缩压变异性、夜间舒张压/收缩压变异性降低,且观察组变化幅度与对照组比较有差异(P<0.05)。观察组不良反应发生率与对照组比较无差异(P>0.05)。结论:联合使用贝前列素钠联合沙库巴曲缬沙坦钠片治疗可提高疗效,具有较好安全性。Objective:To investigate the effect and safety of beproprost sodium combined with acubactrosovalsartan sodium tablets.Methods:106 patients with essential hypertension and early renal dysfunction diagnosed in our hospital from June 2022 to December 2023 were divided into control group and observation group,and 53 patients were selected in each group.Matched group:beproprost sodium,observation group:Shakubatrivalsartan sodium tablets+beproprost sodium.Compare the two groups of related indicators.Results:Compared with the matched group,the observation group had a high efficacy(P<0.05).After treatment,both groups decreased CCr,Cys C,β2-MG,MAU levels,eGFR,24 h diastolic/SBP,nocturnal diastolic/SBP,and the magnitude of change in the observed group was different compared with the control group(P<0.05).The incidence of adverse reactions in the observed group was not different from the matched group(P>0.05).Conclusion:The combination of beproprost sodium with sulbactrosovalsartan sodium tablets may improve the efficacy and safety.

关 键 词：贝前列素钠 原发性高血压合并早期肾功能不全 沙库巴曲缬沙坦钠片 

分 类 号：R544.1[医药卫生—心血管疾病]